Oral Drug Slows Stargardt Disease Progression in Phase 2 Clinical Trial

Tuesday, March 5 2024 | 08 h 05 min | Vision Science

Results from a Phase 2 clinical trial show that an oral drug, Tinlarebant, may slow progression of Stargardt disease.

Belite Bio, a biopharmaceutical company who sponsored this trial, presented data from 12 patients, aged 12-18, who had been treated with Tinlarebant for 2 years. The study found that Tinlarebant was safe and patients who were taking the drug had reduced retinal atrophy. The majority of patients also had stabilized visual acuity during the trial.

Tinlarebant is a drug that is designed to reduce the accumulation of vitamin A-based toxins (bisretinoides) that can cause retinal degeneration in Stargardt disease and advanced dry age-related macular degeneration (also called geographic atrophy). Tinlarebant is also being studied in a Phase 3 trial (PHOENIX) for geographic atrophy.

About Fighting Blindness Canada

Fighting Blindness Canada (FBC) is the largest charitable funder of vision research in Canada.

Over our 49-year history, FBC has contributed critical funding for the development of sight-saving treatments and cures for blinding eye diseases. By raising and stewarding funds, FBC is helping drive forward research that supports our goal of understanding why vision loss occurs, how it can be slowed and how sight can be restored.

We are an invaluable resource for individuals and families impacted by blindness, providing accurate eye health information through our website and educational events, as well as engaging with government and other stakeholders to advance better vision health policies.

Want to see more like this article? Click here to subscribe to our FREE print magazines and e- newsletters!